A Study of S-740792 in Healthy Adult Study Participants
NCT ID: NCT06724978
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
99 participants
INTERVENTIONAL
2024-11-21
2025-09-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
NCT04537897
Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
NCT03637049
Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects
NCT01989169
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
NCT05738291
A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects
NCT04492709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1 (Single Ascending Dose)
Participants will receive S-740792 or placebo.
S-740792 Suspension
Participants will receive S-740792 as an oral suspension.
Placebo
Participants will receive placebo as an oral suspension.
Part 2 (Multiple Ascending Dose)
Participants will receive S-740792 or placebo, in addition to midazolam.
S-740792 Suspension
Participants will receive S-740792 as an oral suspension.
Midazolam
Participants will receive midazolam as a syrup.
Placebo
Participants will receive placebo as an oral suspension.
Part 3 (Bioavailability)
Participants will receive S-740792 as a suspension and as a tablet.
S-740792 Suspension
Participants will receive S-740792 as an oral suspension.
S-740792 Tablet
Participants will receive S-740792 as an oral tablet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S-740792 Suspension
Participants will receive S-740792 as an oral suspension.
Midazolam
Participants will receive midazolam as a syrup.
Placebo
Participants will receive placebo as an oral suspension.
S-740792 Tablet
Participants will receive S-740792 as an oral tablet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Participants who require medication or other treatment (for example, dietary restrictions or physical therapy).
* Participants who have participated in any other clinical study involving an investigational study intervention or any other type of medical research within 28 days or 5 half-lives of that drug (if known), whichever is longer before signing of the informed consent form for this study or who are currently participating in such a study.
* Positive test results of the following at screening or within 6 months prior to administration of study intervention:
* hepatitis B surface antigen
* hepatitis C virus antibody
* serological test for syphilis
* human immunodeficiency virus antigen/antibody
* drug screen
* alcohol screen
* Participants who have used tobacco or nicotine-containing products (including electronic-cigarette, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 6 months prior to admission or a positive cotinine test at screening or on admission.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shionogi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fortrea Clinical Research Unit, Inc.
Daytona Beach, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2318VA711
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.